Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of inhaled steroids

Next Previous
X
Search
Trial Profile

Rationale for therapy with low dose steroids combined with long-acting beta2-agonists in patients with allergic asthma: redirecting innate immune responses by long-term treatment with high doses of inhaled steroids

Status: Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Salmeterol/fluticasone propionate (Primary) ; Fluticasone propionate
  • Indications Asthma
  • Focus Biomarker; Therapeutic Use
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 16 Apr 2015 Status changed from discontinued to withdrawn prior to enrolment as reported by ClinicalTrials.gov
    • 01 Apr 2009 Planned end date (Dec 2007) added as reported by ClinicalTrials.gov.
    • 15 Oct 2008 Actual start date changed from Sep 2007 to Dec 2007 as reported by Clinicaltrials.gov

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top